



Atty. Dkt. No. 072121-0307  
(19099.004)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Paul A. Barsanti, et al.  
Title: BENZIMIDAZOLE  
QUINOLINONES AND USES  
THEREOF  
Appl. No.: 10/644,055  
Filing Date: August 19, 2003  
Art Unit: 1614

<p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><b>Bernard P. Friedrichsen</b> (Printed Name)</p> <p><i>Bernard P. Friedrichsen</i> (Signature)</p> <p><b>August 8, 2005</b> (Date of Deposit)</p>
---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b).

Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

08/11/2005 FMEYK11 00000059 502350 10644055

01 FC:1806 180.00 DA

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR § 1.97(b)(3), before the mailing date of the first Office Action on the merits. In the event that an Office Action on the merits has been mailed to applicants, then the listed documents are being submitted in compliance with 37 CFR § 1.97(c)(2), and the Commissioner is hereby authorized to charge the fee of \$180.00 (Fee Code 1806) set forth in 37 CFR § 1.97(c)(2) and § 1.17(p) to Deposit Account No. 50-2350 for such purpose. The fee is not to be charged to the Deposit Account unless an Office Action on the merits has been mailed to Applicants. The listed documents were cited in a Notice of References Cited for a related United States patent application (USSN 10/116,117) along with an Office Action dated July 13, 2005.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date August 8, 2005

By 

FOLEY & LARDNER LLP  
Customer Number: 23524  
Telephone: (608) 258-4281  
Facsimile: (608) 258-4258

Bernard P. Friedrichsen  
Attorney for Applicants  
Registration No. 44,689

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/644,055
Date Submitted: August 8, 2005		<b>Filing Date</b>	08/19/2003
(use as many sheets as necessary)		<b>First Named Inventor</b>	Paul A. Barsanti
Sheet 1 of 2		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	
		<b>Attorney Docket Number</b>	072121-0307

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Zetter, B. R., "Angiogenesis and Tumor Metastasis," Annu. Rev. Med., 1998, Vol. 49, pp. 407-24; published by Annual Review Inc.	
		MSNBC News Services, "Mixed results on new cancer drug," November 9, 2000.	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: August 8, 2005  (use as many sheets as necessary)		Application Number	10/644,055
		Filing Date	08/19/2003
		First Named Inventor	Paul A. Barsanti
		Group Art Unit	1614
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	072121-0307	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> , 1997, Vol. 278, pp. 1041-1042.	
		Dermer, G. B., "Another Anniversary for the War on Cancer," <i>Biotechnology</i> , 1994, Vol. 12, p. 320.	
		Freshney, R. I., <i>Culture of Animal Cells – A Manual of Basic Technique</i> , 1983, pp. 1-4; published by Alan R. Liss, Inc.	
		Angiogenesis Foundation, "New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent," January 4, 2000; <a href="http://www.angio.org/newsandviews/archive2000/jan_4_2000.html">www.angio.org/newsandviews/archive2000/jan_4_2000.html</a> .	
		Hussong, J. W. <i>et al.</i> , "Evidence of increased angiogenesis in acute myeloid leukemia," <i>Blood</i> , 2000, Vol. 95(1), pp. 309-313; The American Society of Hematology.	
		Kerbel, R. S., "Tumor Angiogenesis: Past, Present and Near Future," <i>Carcinogenesis</i> , 2000, Vol. 21(3), pp. 505-515; Oxford University Press.	
		Lundberg, L. G. <i>et al.</i> , "Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity," <i>American Journal of Pathology</i> , 2000, Vol. 157(1), pp. 15-19.	
		Dankbar, B. <i>et al.</i> , "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma," <i>Blood</i> , 2000, Vol. 95(8), pp. 2630-2636.	
		Menzel, T. <i>et al.</i> , "Elevated Intracellular Level of Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and is Associated With Resistance to Fludarabine," <i>Blood</i> , 1996, Vol. 87(3), pp. 1056-1063.	
		Gruber, G. <i>et al.</i> , "Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia," <i>Blood</i> , 1999, Vol. 94(3), pp. 1077-1085.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.